Gout study aims to predict crystal dissolution time
NCT ID NCT06669000
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 250 adults with gout to see how long it takes for urate crystals in the joints to dissolve when uric acid levels are kept below 40 mg/L. Participants will have regular ultrasounds of their feet and knees to track crystal disappearance. The goal is to identify factors that affect dissolution time, which could help personalize gout treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors predict how long gout patients need treatment to dissolve urate crystals and achieve remission.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test a new drug or cure, and results may not apply to all gout patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Sep 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Gout patient managed according to a T2T (treat to target) strategy
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age over 18 years * Gout according to the ACR/Eular 2015 criteria * SUA levels greater than 60 mg/L * US score (MTP1s, knees) ≥2/24 * Informed consent Dated and signed voluntarily Exclusion Criteria: * Ongoing urate lowering therapy * Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases * Pregnant or breast-feeding women * No affiliation to the French National Social Security System
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gout are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
APHP, Lariboisière Hospital, Rheumatology departement
RECRUITINGParis, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily pill tame Gout's uric acid?
- Can a new drug combo crack Hard-to-Treat gout?
- Can a diabetes drug fight gout? metformin takes on febuxostat
- Can a weekly weight drug quiet gout attacks?
- Gout's crystal clues: could urate deposits flag hidden heart risk?
- Can a new injection tame Gout's uric acid?